Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Solid Tumors 2Neoplasms 2Melanoma 2Recurrence 1Pancreatic Adenocarcinoma 1Lymphoma, B-Cell 1Colorectal Neoplasms 1Breast Neoplasms 1Advanced/Metastatic Solid Tumors 1Adenocarcinoma Pancreas 1

Interventions

Gemcitabine 13Albumin-Bound Paclitaxel 8Taxes 6130-nm albumin-bound paclitaxel 6Fluorouracil 5Oxaliplatin 4dehydroftorafur 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Leucovorin 3Irinotecan 3Losartan 2Cisplatin 2tocilizumab 1selicrelumab 1niraparib 1irinotecan sucrosofate 1indusatumab 1folfirinox 1durvalumab 1cobimetinib 1atezolizumab 1X-Rays 1Tiragolumab 1Surgical Procedures, Operative 1Standard of Care 1Specimen Handling 1S 1 (combination) 1Resistance Training 1Radiotherapy, Image-Guided 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Adenocarcinoma × selicrelumab × Clear all
NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hoffmann-La Roche

Phase 1/2 Completed
341 enrolled 28 charts
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡